HCPCS code J3111: Injection, romosozumab-aqqg billing guide

Key Takeaways

HCPCS code J3111 describes injection of romosozumab-aqqg (Evenity) at 1 mg per billable unit, meaning each 210 mg dose requires 210 units on the claim.

Medicare Part B claims for J3111 require either the JW modifier (drug discarded) or JZ modifier (no drug discarded) on every single-dose container claim.

Prior authorization is required by most commercial payers before administering Evenity, and medical necessity must be supported by a documented T-score and treatment history.

Pabau’s claims management software helps practices track J-code billing workflows, prior authorization status, and modifier requirements across payers.

HCPCS code J3111 is the billing code for injection of romosozumab-aqqg (Evenity) at 1 mg per unit, so the standard 210 mg dose bills as 210 units. Missing the JW or JZ modifier on a single-dose vial claim is the most common reason these claims get rejected.

Specialty practice billing teams also run into denials when prior authorization wasn’t secured before the injection was administered.

This guide covers J3111’s definition and unit calculation, Medicare Part B reimbursement, JW/JZ modifier rules, prior authorization criteria, related administration codes, and the ICD-10 codes needed for a clean claim.

New to billing terminology? Our medical billing basics guide covers the fundamentals before you dig into J-code specifics.

HCPCS code J3111: definition and code properties

HCPCS code J3111 is defined by CMS (the Centers for Medicare and Medicaid Services) as: Injection, romosozumab-aqqg, 1 mg. One billable unit equals 1 mg. J3111 is the J code for Evenity, so a search for the Evenity HCPCS code or the J code for Evenity points to this same identifier.

At the standard 210 mg dose, J3111 billing units total 210. The code sits within HCPCS Level II’s “Drugs Administered Other than Oral Method” category (J0120-J8999), specifically the J0013-J7175 injectable drug range.

The “-aqqg” suffix in romosozumab-aqqg is a biological qualifier assigned by the FDA. It distinguishes the originator biologic (Amgen’s Evenity) from any future biosimilar entrants. Never substitute a biosimilar without confirming its own dedicated HCPCS code.

CMS Transmittal R10274CP (CR 11846) confirms that when romosozumab-aqqg is billed under the Medicare home health agency benefit, it is reported using HCPCS code J3111, provided home health coverage guidelines are met.

A common error in the field: one online source incorrectly describes J3111 as “Injection, denosumab, 1 mg.” Denosumab is a completely different biologic, billed under HCPCS J0897 for both Prolia and Xgeva. Always confirm the code description against CMS or AAPC Codify’s HCPCS lookup before submitting a claim.

A built-in code verification step in your billing software catches these substitution errors at the point of entry. Also see how practices use IVF CPT codes as a model for unit-based drug billing.

Is J3111 a CPT or HCPCS code?

J3111 is an HCPCS Level II code, not a CPT code. Coders often search for the J3111 CPT code or CPT code J3111, but CPT is a separate code set maintained by the American Medical Association for procedures and services.

HCPCS Level II codes like J3111 identify the drug itself. The J3111 CPT code description people expect is actually the HCPCS descriptor: injection, romosozumab-aqqg, 1 mg. A true CPT code applies to the act of administering the drug (96372, covered below), not to the drug.

Medicare Part B reimbursement and fee schedule methodology

J3111 Medicare reimbursement follows the Buy-and-Bill model at Average Sales Price (ASP) plus 6%. CMS updates the ASP+6% rate quarterly to reflect the manufacturer’s volume-weighted average net sales price across all commercial customers. Never hardcode a dollar figure for J3111 reimbursement into billing workflows. The rate changes every quarter.

For practices that cannot secure favorable ASP pricing, CMS provides an alternative reimbursement floor at Wholesale Acquisition Cost (WAC) plus 3%. This applies when the ASP data is unavailable or the product is new to market. The CMS fee schedule tool lets you verify the current quarter’s allowable for J3111 by geographic locality before submitting claims.

Place of service and site-of-care considerations

Reimbursement for J3111 varies by place of service. Physician offices (POS 11) typically receive a higher total payment than hospital outpatient departments (POS 22) under Medicare’s different facility and non-facility rate structures.

Infusion centers billed under a hospital provider number operate under the OPPS (Outpatient Prospective Payment System) rather than the Physician Fee Schedule. This can change the net reimbursement picture substantially.

• POS 11 (Physician office): Non-facility rate applies. The practice buys and bills the drug directly.
• POS 22 (Hospital outpatient): Facility rate applies. OPPS separately reimburses the drug under APC grouping.
• POS 65 (End Stage Renal Disease facility): Rarely applicable for osteoporosis indications. Confirm coverage.
• POS 19/21 (Outpatient hospital/Inpatient): Drug typically bundled. Standalone J3111 billing may not apply.

Commercial payers may follow the Medicare methodology or apply their own contracted rates. Always verify the contracted rate for J3111 in each payer agreement before assuming ASP+6% is the payment floor. Unit accuracy and place-of-service accuracy are both non-negotiable for a clean claim submission.

JW and JZ modifier requirements for HCPCS code J3111

Medicare Part B requires either the JW or JZ modifier on every J3111 claim involving a single-dose container. Amgen packages Evenity as single-use prefilled syringes, so this requirement applies to virtually all clinical administrations. Omitting the modifier is one of the most common reasons J3111 claims are rejected on first submission.

Evenity is administered as two 105 mg syringes totaling 210 mg, so most administrations use the JZ modifier with no waste. If a patient receives less than the full dose for any clinical reason, the JW modifier applies to the discarded portion. Document both modifiers in the patient record to support the claim.

The Amgen Evenity coding and billing guide confirms that Medicare Part B claims for single-dose containers require a JW or JZ modifier. Report the modifier in the claim’s modifier field alongside HCPCS code J3111, following CMS JW/JZ modifier billing guidance.

Documentation to support modifier selection

The patient record must reflect which modifier applies. For JZ: document the full dose administered and the lot numbers of both syringes. For JW: document the dose administered, the amount discarded, and the clinical reason for partial administration. Auditors look for exact mg amounts in the clinical note. Vague entries like “Evenity administered per protocol” are insufficient for modifier defense.

Strong modifier documentation protects claims across every specialty area, not just osteoporosis billing. A one-line clinical note naming the modifier, units administered, and any waste amount is what separates a paid claim from a recoupment risk. Using HIPAA-compliant documentation practices in your clinical records helps keep every payer audit-ready.

Simplify J-code billing with Pabau

Pabau's claims management tools help practices track modifier requirements, prior authorization status, and payer-specific rules for J-codes like J3111, so billing teams spend less time on rejections and more time on care.

Book a demo

Prior authorization requirements for HCPCS code J3111

Most commercial payers require prior authorization (PA) before administering Evenity. Medical Mutual’s prior authorization policy confirms PA is required for J3111 (Evenity) as of April 2024. Moda Health’s medical necessity criteria document outlines specific clinical thresholds that must be documented in the PA request.

Medicare does not require prior authorization for most Part B drugs under the Buy-and-Bill model, but Medicare Advantage plans vary widely. Confirm with each plan individually whether a J3111 PA is required before administering the first dose.

Medical necessity criteria coders need to document

PA requests for J3111 are typically evaluated against bone mineral density (BMD) thresholds and treatment history. Most payer criteria require the PA request to document all of the following before approving HCPCS code J3111:

• A 77080 bone density scan confirms postmenopausal osteoporosis diagnosis with T-score at or below -2.5 (or -1.0 with fragility fracture history, depending on payer)
• High fracture risk determination by the prescribing physician
• Failure of or contraindication to prior bisphosphonate therapy, such as zoledronic acid (J3489), or another antiresorptive (payer-specific, but commonly required)
• Documentation that the patient has not already completed the 12-month maximum treatment duration for romosozumab
• Prescriber documentation that the patient meets cardiovascular risk thresholds per FDA labeling (romosozumab carries a cardiovascular risk boxed warning)

T-score cutoffs and bisphosphonate failure requirements differ across payers. Never present one payer’s criteria as universal. Moda Health’s criteria, for example, reflect their specific formulary policy, while another payer may apply different thresholds.

Document every clinical criterion the PA form requests, even if it seems clinically obvious. Missing PA documentation is a top cause of post-service denials for J3111. Strong prescription management software can track PA expiration dates and renewal windows to prevent coverage lapses on repeat Evenity doses.

Related administration CPT codes and NDC reporting

Billing J3111 correctly means pairing it with the right administration CPT code. Clinicians administer romosozumab subcutaneously, so CPT 96372 (therapeutic, prophylactic, or diagnostic injection, subcutaneous or intramuscular) covers the administration itself.

This administration code is billed separately from J3111 under most payers, including Medicare, when performed in a non-facility setting. J3111 covers the drug itself, while CPT 96372 covers administering it.

NDC reporting requirements

Many commercial payers and some state Medicaid programs require the National Drug Code (NDC) on J3111 claims in addition to the HCPCS code. The NDC identifies the exact product dispensed, including manufacturer, strength, and package type.

Evenity NDCs confirmed in Moda Health’s medical necessity criteria document:

• 55513-0880-xx: Evenity 105 mg/1.17 mL single-use plastic prefilled syringe (carton of two)
• 55513-0998-xx: Evenity 105 mg/1.17 mL single-use glass prefilled syringe (carton of two)

The “xx” at the end represents the package size code, which varies by lot. Report the J3111 NDC in the 5-4-2 format (5-digit labeler, 4-digit product, 2-digit package) when required. The NDC qualifier “N4” typically precedes the NDC number on electronic claims.

Confirm with each payer whether NDC reporting is required, since the Physician Fee Schedule does not universally mandate it on Medicare Part B claims. Apply the same payer-specific verification approach you use for HCPCS and CPT codes to NDC reporting on every J-code claim.

ICD-10 diagnosis codes that support HCPCS code J3111 claims

J3111 claims require a supporting ICD-10-CM diagnosis code that establishes medical necessity. The FDA approved romosozumab for postmenopausal osteoporosis with high fracture risk. The ICD-10 codes that most commonly support J3111 come from the M80 and M81 categories.

Payers may maintain local coverage determination (LCD) or coverage policies that restrict J3111 to specific ICD-10 codes. Always cross-reference the payer’s LCD or medical necessity policy for J3111 before selecting the diagnosis code.

Some payers require the site-specific M80 fracture code rather than the unspecified version. Submitting an unspecified code when a site is documented in the clinical record can trigger a medical necessity denial. The same specificity applies earlier in the diagnostic path. Z13.820, used for an osteoporosis screening encounter, requires its own supporting documentation.

Documentation and compliance considerations for J3111

A complete J3111 claim record includes more than just the code and modifier. Auditors reviewing J3111 claims under a post-payment audit look for a specific set of clinical documentation elements in the patient chart.

• DXA scan report with T-score at the relevant anatomical site (lumbar spine or hip preferred)
• Documented diagnosis of osteoporosis with high fracture risk notation from the prescriber
• Record of prior osteoporosis treatment (or documented contraindication/intolerance)
• Cardiovascular risk assessment acknowledging FDA boxed warning
• Injection administration record with lot number, NDC, site of injection, units administered, and any discarded amount
• JW or JZ modifier selection documented in the chart note
• Signed patient consent acknowledging cardiovascular risk

Digital intake and clinical documentation tools significantly reduce missing-field audit risk. Digital intake forms built around J3111 documentation requirements ensure the chart contains every field auditors expect before the claim is submitted. This is especially useful for high-volume osteoporosis practices administering Evenity monthly.

The PGM Billing lookup tool provides free access to CMS HCPCS data, useful for verifying J3111 code properties and cross-referencing related codes during claim preparation.

Pairing this documentation checklist with a structured plan, like our osteoporosis care plan template, keeps clinical and billing records aligned across every Evenity dose.

Conclusion

HCPCS code J3111 is a high-value drug code with billing rules precise enough that modifier omissions, incorrect unit counts, or missing PA documentation consistently trigger denials. The JW/JZ modifier requirement alone accounts for a significant share of first-pass rejections on Evenity claims.

Pabau’s claims management software helps specialty practices track modifier requirements, prior authorization deadlines, and payer-specific rules for J-codes including J3111, cutting down on the manual tracking that leads to billing errors. To see how Pabau can support your J-code billing workflow, book a demo with the team.

Continue your research

Need to verify related osteoporosis treatment codes? IVF CPT codes illustrate how unit-based drug billing works across specialty treatment courses.

Building a complete billing documentation workflow? Digital intake forms let practices capture injection records, modifier documentation, and NDC details in structured clinical forms.

Concerned about HIPAA compliance in your billing records? Our HIPAA compliance guide covers the documentation standards that protect your practice during audit.

Recently published: K71.2 covers toxic liver disease with acute hepatitis, a useful reference for practices that also code drug-induced conditions.

Recently published: 01320 covers anesthesia billing for knee and popliteal area procedures.

Recently published: 01925 covers anesthesia for carotid or coronary interventional radiology procedures.

Frequently asked questions